Darya Danilenko, Deputy Director for Research of the Research Institute of Flu, spoke about this during the St. Petersburg International Health Forum.
She said that "Corfluvek" is being developed on the basis of an attenuated influenza vector.
"At the moment, preclinical studies of this vaccine have been completed, and clinical trials will begin in the very near future," TASS quotes her as saying.
Danilenko expressed hope that the drug will be registered next year.
Earlier, the Ministry of Health allowed clinical trials of a nasal vaccine against coronavirus developed by the Gamaleya Center.